<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422006</url>
  </required_header>
  <id_info>
    <org_study_id>BRD 06/8-I</org_study_id>
    <secondary_id>ID RCB 2006-A00196-45</secondary_id>
    <secondary_id>DGS2006-0090</secondary_id>
    <nct_id>NCT00422006</nct_id>
  </id_info>
  <brief_title>Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance</brief_title>
  <official_title>Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experimental results are strongly suggesting that PCSK9 and FXR could occur in the
      physiopathology of human joined dyslipidemia. But no data in the literature can validate the
      potential role of these two genes in the lipidic and glucidic metabolism control in
      physiopathological situations. This protocol is based on the hypothesis that the expression
      levels of PCSK 9 and FXR are modified for some patients suffering from insulin resistance and
      dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the relationship between the expression levels of PCSK9 and FXR in the liver, adipose tissue and muscle and the different components of the insulin resistance syndrome obese patients submitted to bariatric surgery</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between the levels of hepatic expression of PCSK9 and FXR and the degree of NASH in these patients. - Search for mutations and polymorphisms in the gene PCSK9 and FXR and their promoter regions</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non diabetic non dyslipidemic patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with metabolic syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with type II diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with a single lipidic anomaly</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy of muscle, of liver, and of adipose tissue</intervention_name>
    <description>biopsy of muscle, of liver, and of adipose tissue</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>clamp euglycemic - hyperglycemic</intervention_name>
    <description>clamp euglycemic-hyperglycemic</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>diet</intervention_name>
    <description>diet</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biopsies for biological and genetic analyses</intervention_name>
    <description>biopsies for biological and genetic analyses</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  corporal mass index &gt; 40 kg/m² or &gt; 35 kg/m² associated to a co-morbidity resistant to
             a diet

          -  bariatric surgery planned

          -  no lipid-lowering drugs during 4 weeks before surgery

          -  no treatment by metformin during 4 weeks before surgery

          -  no treatment by glitazones during 8 weeks before surgery

          -  age of the patient between 18 and 65 years

          -  consent form signed

          -  patient with social insurance

        Exclusion Criteria:

          -  age inferior to 18 years

          -  women pregnant

          -  coagulation troubles

          -  surgery contraindicated

          -  Chronic hepatitis B or C active

          -  VIH infected

          -  other chronic hepatic disease

          -  patient with dyslipidemia under lipid-lowering drugs in secondary prevention of a
             cardiovascular pathology

          -  Type 2 diabetes under insulinosensitivator treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Cariou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Krempf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yassine Zaïr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Letessier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Couet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Tours</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noël Huten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Tours</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Topart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Lechaux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de St Brieuc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Pierre Faure, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poitiers University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2007</study_first_posted>
  <last_update_submitted>April 2, 2014</last_update_submitted>
  <last_update_submitted_qc>April 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bariatric surgery planned</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

